Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts.
about
Reversibility of liver fibrosisBone marrow derived stem cells for the treatment of end-stage liver diseaseReversibility and heritability of liver fibrosis: Implications for research and therapyTargeting Mechanotransduction at the Transcriptional Level: YAP and BRD4 Are Novel Therapeutic Targets for the Reversal of Liver FibrosisAdiponectin agonist ADP355 attenuates CCl4-induced liver fibrosis in miceABO-compatible liver allograft antibody-mediated rejection: an update.Loss of pericyte smoothened activity in mice with genetic deficiency of leptin.Inhibition of acidic sphingomyelinase reduces established hepatic fibrosis in miceRegulatory Effects and Mechanism of Adenovirus-Mediated PTEN Gene on Hepatic Stellate Cells.In vitro reversion of activated primary human hepatic stellate cellsReversibility of Stricturing Crohn's Disease-Fact or Fiction?Long noncoding RNAs expressed in human hepatic stellate cells form networks with extracellular matrix proteins.Mechanisms of Lung Fibrosis Resolution.The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies.Early to Phase II drugs currently under investigation for the treatment of liver fibrosis.New therapies for hepatic fibrosis.FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients.New Developments on the Treatment of Liver Fibrosis.Reversibility of liver fibrosis.Spotlight on the three main hepatic fibrogenic cells in HCV-infected patients: Multiple immunofluorescence and ultrastructure study.Cytoresistance after acute kidney injury is limited to the recovery period of proximal tubule integrity and possibly involves Hippo-YAP signaling.Tricyclic Antidepressants Promote Ceramide Accumulation to Regulate Collagen Production in Human Hepatic Stellate Cells.Molecular targets for antifibrotic therapy in liver disease: using magic bullets for crossfire rather than a one-sided shotgun attack.Research highlights: aptamers on a chip.2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection.The Role of Metabolic Surgery in Non-alcoholic Steatohepatitis Improvement.Relevance of activated hepatic stellate cells in predicting the development of pediatric liver allograft fibrosis.Analysis of Pathological Activities of CCN Proteins in Fibrotic Diseases: Liver Fibrosis.Key Anti-Fibrosis Associated Long Noncoding RNAs Identified in Human Hepatic Stellate Cell via Transcriptome Sequencing Analysis.CD147 Promotes CXCL1 Expression and Modulates Liver Fibrogenesis.Transforming Growth Factor-β-Induced Cell Plasticity in Liver Fibrosis and Hepatocarcinogenesis
P2860
Q26822053-B9B08F70-80FF-4D7C-9286-CD4A4CB2EE79Q26850412-33EA826F-CAE2-4486-8405-4D6DE787DC1EQ27026622-13B4D0BE-4184-4957-AF61-10F357BCCEF8Q28070012-5E104D8C-5ED5-4292-8319-204328E69F0CQ28543721-BB3F2D1A-773F-4EC1-8B7F-CF7E21CD16F4Q33422561-DCF904B0-7FB8-4D36-923D-399BF7912101Q33587672-FF6E09C9-E655-4D51-A220-9C239006B94BQ34451277-11A4FA4F-BF08-4ADD-8B9F-A98A4B60F6FFQ35867605-7BC67753-9014-4FA8-9696-6BC2DFB3A520Q35923294-7C4C36F7-D4BB-4045-9E18-A6568864E545Q36373253-A5327664-D6EE-4F00-9D20-DEC4DAD14964Q36720404-43B4BA49-CD53-4CBD-BB70-7A17BBD4FEE4Q36885732-F8C67548-F991-4C04-A969-166C012AA60CQ38237634-98403D93-E695-4A81-8ED2-C4493C56F8CDQ38303313-62420E95-C484-4ED3-AE1E-62332E36EF81Q38553309-FE816A68-0ECF-4EC8-A75A-0ACF92AD68C8Q38679137-5F7F3B07-A908-4C72-B0C4-6513828C56A1Q38873303-0BF0DBAA-AE0F-4676-BC5B-16033A1D5C6CQ38886975-01293359-B1FE-4B6F-AD20-97A05FB325D6Q40615522-8F818991-F417-4036-98DA-A8D59E727382Q42180498-318252FC-4C35-482E-A265-D81D8F7DC03AQ42315013-79B10505-3E70-4378-BF6F-AF8CC6FE240CQ43898859-A5D8C460-38FB-48A5-A887-6B8CE32CD395Q46128780-14959B03-51B8-4825-B045-46F18EF2CF9CQ46360525-EA8171EF-5693-4F09-A5A5-7E7344BE5B4BQ47847024-696DBCA3-DA6E-425D-9A91-EA64A9078578Q50262412-652F646D-C22E-4F69-9AEA-57A405554D95Q50484274-9E6D8CF7-6725-422F-9523-791E21C4AC5CQ52370723-EDC6667E-C722-4C88-95C3-AE344E87042AQ54942693-D09E951C-D2B0-4F8E-835A-2F280B570626Q58754397-4F42E806-D42A-454B-9777-FBAC261C800B
P2860
Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts.
@en
Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts.
@nl
type
label
Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts.
@en
Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts.
@nl
prefLabel
Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts.
@en
Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts.
@nl
P2093
P2860
P1476
Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts.
@en
P2093
Tatiana Kisseleva
P2860
P2888
P304
P356
10.1007/S40139-013-0018-7
P577
2013-09-01T00:00:00Z